# Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT04402541** · PHASE1 · COMPLETED · sponsor: **Cleave Therapeutics, Inc.** · enrollment: 55 (actual)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** CB-5339

## Key facts

- **NCT ID:** NCT04402541
- **Lead sponsor:** Cleave Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-08
- **Primary completion:** 2023-07-23
- **Final completion:** 2023-07-23
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402541, "Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04402541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*